You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Trandolapril did not reduce cardiovascular death or other events in stable coronary artery disease

https://doi.org/10.1136/ebm.10.3.78

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058–68.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In patients with stable coronary artery disease (CAD) and preserved left ventricular (LV) function, is trandolapril better than placebo for reducing the risk of cardiovascular (CV) death or other CV events?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Cardiology ★★★★★★☆

    METHODS

    Embedded ImageDesign:

    randomised placebo controlled trial (Prevention of Events with Angiotensin Converting Enzyme Inhibition [PEACE] trial).

    Embedded ImageAllocation:

    concealed.*

    Embedded ImageBlinding:

    blinded (clinicians, patients, {data collectors, and outcome assessors}†).*

    Embedded ImageFollow up period:

    median 4.8 years.

    Embedded ImageSetting:

    187 centres in the US, Canada, and Italy.

    Embedded ImagePatients:

    8290 patients (mean age 64 y, 82% men) who had documented CAD (⩾1 of myocardial infarction [MI], coronary artery bypass grafting [CABG] or percutaneous coronary intervention [PCI] ⩾3 months before enrolment; or obstruction of ⩾50% of the luminal diameter of ⩾1 native vessel or coronary angiography); LV ejection fraction >40% on ventriculography or echocardiograpy, a qualitatively normal left ventriculogram, or the absence of LV wall motion abnormalities on echocardiography; …

    View Full Text

    Footnotes

    • ↵* *See glossary.

    • ↵† Information provided by author.

    • For correspondence: Dr E Braunwald, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA, USA. ebraunwaldpartners.org

    • Sources of funding: National Heart, Lung and Blood Institute; Knoll Pharmaceuticals; Abbott Laboratories.